{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:07:43Z","timestamp":1768813663081,"version":"3.49.0"},"reference-count":49,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T00:00:00Z","timestamp":1713312000000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2024,3,11]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hepatorenal syndrome (HRS), a multiorgan condition of acute kidney injury, is seen in advanced liver disease. This study aims to evaluate the current treatment for HRS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The authors searched PubMed, Scopus and Google Scholar literature. After quality assessment, 31 studies were included in this review. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses methodology and the population, intervention, comparison and outcome scheme were used. We included human-controlled trials that evaluate the current treatment for HRS. Two authors independently screened articles for inclusion, extracted data and assessed the quality of included studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study investigated the studies conducted on the effects of different treatments on follow-up of HRS patients. We gathered 440 articles, so 31 articles remained in our study. Of which 24 articles were conducted on terlipressin versus placebo or other treatments (midodrine\/octreotide, norepinephrine, etc) that showed the higher rate of HRS reversal was detected for terlipressin in 17 studies (10 of them were significant), 2 studies achieved an insignificant lower rate of the model for end-stage liver disease score for terlipressin, 15 studies showed a decreased mortality rate in the terlipressin group (4 of them were significant).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This review showed that terlipressin has a significantly higher reversal rate of HRS than the other treatments. Even the results showed that terlipressin is more efficient than midodrine\/octreotide and norepinephrine as a previous medication, in reverse HRS, increasing patient survival.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgast-2023-001319","type":"journal-article","created":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T12:40:52Z","timestamp":1713357652000},"page":"e001319","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Management of hepatorenal syndrome and associated outcomes: a systematic review"],"prefix":"10.1136","volume":"11","author":[{"given":"Jamshid","family":"Roozbeh","sequence":"first","affiliation":[{"name":"Shiraz University of Medical Sciences, shiraz, Iran (the Islamic Republic of)"},{"name":"Shiraz Nephro-Urology Research Center, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh","family":"Ezzatzadegan Jahromi","sequence":"additional","affiliation":[{"name":"Shiraz University of Medical Sciences, shiraz, Iran (the Islamic Republic of)"},{"name":"Shiraz Nephro-Urology Research Center, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad Hossein","family":"Rezazadeh","sequence":"additional","affiliation":[{"name":"Shiraz University of Medical Sciences, shiraz, Iran (the Islamic Republic of)"},{"name":"Shiraz Nephro-Urology Research Center, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anahid","family":"Hamidianjahromi","sequence":"additional","affiliation":[{"name":"Shiraz University of Medical Sciences, shiraz, Iran (the Islamic Republic of)"},{"name":"Shiraz Nephro-Urology Research Center, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3868-9523","authenticated-orcid":false,"given":"Leila","family":"Malekmakan","sequence":"additional","affiliation":[{"name":"Shiraz University of Medical Sciences, shiraz, Iran (the Islamic Republic of)"},{"name":"Shiraz Nephro-Urology Research Center, Shiraz, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,4,17]]},"reference":[{"key":"2025073013074418000_11.1.e001319.1","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/jhbp.1143","article-title":"Effect of the response to preoperative treatment for hepatorenal syndrome on the outcome of recipients of living\u2010donor liver transplantation","volume":"29","author":"Takahashi","year":"2022","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2025073013074418000_11.1.e001319.2","unstructured":"Al Pje: PRISMA 2020 explanation and elaboration: updated guidance and Exemplars for reporting systematic reviews. BMJ 2021."},{"key":"2025073013074418000_11.1.e001319.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.05.004"},{"key":"2025073013074418000_11.1.e001319.4","doi-asserted-by":"crossref","unstructured":"Simonetto DA , Gines P , Kamath PS . Hepatorenal syndrome: pathophysiology, diagnosis, and management. BMJ 2020;370. doi:10.1136\/bmj.m2687","DOI":"10.1136\/bmj.m2687"},{"key":"2025073013074418000_11.1.e001319.5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-018-0022-7","article-title":"Hepatorenal syndrome","volume":"4","author":"Gin\u00e8s","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"2025073013074418000_11.1.e001319.6","article-title":"Sapkota B: a review of hepatorenal syndrome","volume":"13","author":"Subedi","year":"2021","journal-title":"Cureus"},{"key":"2025073013074418000_11.1.e001319.7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5527\/wjn.v4.i2.277","article-title":"Y\u0131lmazlar T: management of hepatorenal syndrome","volume":"4","author":"Dundar","year":"2015","journal-title":"World J Nephrol"},{"key":"2025073013074418000_11.1.e001319.8","doi-asserted-by":"crossref","unstructured":"De A , Roy A , Singh V . Renal failure in cirrhosis. In: Clinical Rounds in Hepatology. edn: Springer, 2022: 67\u201374.","DOI":"10.1007\/978-981-16-8448-7_9"},{"key":"2025073013074418000_11.1.e001319.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.07.002"},{"key":"2025073013074418000_11.1.e001319.10","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0006722021"},{"key":"2025073013074418000_11.1.e001319.11","doi-asserted-by":"crossref","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"2025073013074418000_11.1.e001319.12","unstructured":"The HJ: Cochrane Handbook for systematic reviews of interventions version 5.1. 0. 2011."},{"key":"2025073013074418000_11.1.e001319.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008290"},{"key":"2025073013074418000_11.1.e001319.14","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1111\/apt.14052","article-title":"Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT\u20100401 and REVERSE randomised clinical studies","volume":"45","author":"Sanyal","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025073013074418000_11.1.e001319.15","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1053\/j.gastro.2016.02.026","article-title":"Terlipressin plus albumin is more effective than albumin alone in improving renal function in patients with cirrhosis and hepatorenal syndrome type 1","volume":"150","author":"Boyer","year":"2016","journal-title":"Gastroenterology"},{"key":"2025073013074418000_11.1.e001319.16","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.14309\/00000434-201210001-00418","article-title":"Role of terlipressin and albumin combination versus albumin alone in hepatorenal syndrome: 418","volume":"107","author":"Zafar","year":"2012","journal-title":"Am J Gastroenterol Suppl"},{"key":"2025073013074418000_11.1.e001319.17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.024"},{"key":"2025073013074418000_11.1.e001319.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9919-9"},{"key":"2025073013074418000_11.1.e001319.19","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1746.2003.02934.x"},{"key":"2025073013074418000_11.1.e001319.20","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1055\/s-2008-1037659","article-title":"Terlipressin in 33 patients with Hepatorenal syndrome: results of a retrospective study on duration and dose of terlipressin therapy","volume":"46","author":"von Kalckreuth","year":"2008","journal-title":"Z Gastroenterol"},{"key":"2025073013074418000_11.1.e001319.21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28396"},{"key":"2025073013074418000_11.1.e001319.22","doi-asserted-by":"crossref","first-page":"101126","DOI":"10.1016\/j.aohep.2023.101126","article-title":"Mujtaba MA:Terlipressinincombinationwithalbuminasatherapyforhepatorenalsyndromeinpatientsaged65Yearsorolder annals ofHepatology","volume":"28","author":"Mujtaba","year":"2023","journal-title":"Ann Hepatol"},{"key":"2025073013074418000_11.1.e001319.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.04.010"},{"key":"2025073013074418000_11.1.e001319.24","first-page":"13","article-title":"Norepinephrine versus terlipressin in patients with type 1 hepatorenal syndrome refractory to treatment with octreotide, midodrine, and albumin (a prospective randomized comparative study)","volume":"7","author":"Badawy","year":"2013","journal-title":"The Egyptian Journal of Cardiothoracic Anesthesia"},{"key":"2025073013074418000_11.1.e001319.25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30208"},{"key":"2025073013074418000_11.1.e001319.26","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12664-018-0876-3","article-title":"Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome: a randomized controlled study","volume":"37","author":"Saif","year":"2018","journal-title":"Indian J Gastroenterol"},{"key":"2025073013074418000_11.1.e001319.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2008.01828.x"},{"key":"2025073013074418000_11.1.e001319.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.01.012"},{"key":"2025073013074418000_11.1.e001319.29","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/liv.12179","article-title":"Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study","volume":"33","author":"Ghosh","year":"2013","journal-title":"Liver Int"},{"key":"2025073013074418000_11.1.e001319.30","first-page":"30","article-title":"Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: a prospective, randomized trial","volume":"64","author":"Goyal","year":"2016","journal-title":"J Assoc Physicians India"},{"key":"2025073013074418000_11.1.e001319.31","first-page":"S97","article-title":"Noradrenaline is equally effective as terlipressin in reversal of type 1 hepatorenal syndrome: a randomized prospective study","volume":"3","author":"Indrabi","year":"2013","journal-title":"JCEH"},{"key":"2025073013074418000_11.1.e001319.32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s12664-023-01356-6","article-title":"Combination of terlipressin and noradrenaline versus terlipressin in hepatorenal syndrome with early non-response to terlipressin infusion: a randomized trial","volume":"42","author":"Singh","year":"2023","journal-title":"Indian J Gastroenterol"},{"key":"2025073013074418000_11.1.e001319.33","first-page":"1946","article-title":"Efficacy of terlipressin and albumin in the treatment of hepatorenal syndrome","volume":"12","author":"Silawat","year":"2011","journal-title":"World Appl Sci J"},{"key":"2025073013074418000_11.1.e001319.34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jceh.2015.08.003","article-title":"Randomized controlled trial comparing the efficacy of terlipressin and albumin with a combination of concurrent dopamine, furosemide, and albumin in hepatorenal syndrome","volume":"5","author":"Srivastava","year":"2015","journal-title":"J Clin Exp Hepatol"},{"key":"2025073013074418000_11.1.e001319.35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27709"},{"key":"2025073013074418000_11.1.e001319.36","doi-asserted-by":"crossref","unstructured":"Copaci I , Micu L , Chiriac G . Reversal of type I hepato-renal syndrome with terlipressin and octreotide. J Hepatol 2016;64. doi:10.1016\/S0168-8278(16)01240-X","DOI":"10.1016\/S0168-8278(16)01240-X"},{"key":"2025073013074418000_11.1.e001319.37","first-page":"764","article-title":"Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial","volume":"3","author":"Tavakkoli","year":"2012","journal-title":"Int J Prev Med"},{"key":"2025073013074418000_11.1.e001319.38","doi-asserted-by":"crossref","unstructured":"El-Desoki Mahmoud EI , Abdelaziz DH , Abd-Elsalam S , et al . Norepinephrine is more effective than midodrine\/octreotide in patients with hepatorenal syndrome-acute kidney injury: a randomized controlled trial. Front Pharmacol 2021;12. doi:10.3389\/fphar.2021.675948","DOI":"10.3389\/fphar.2021.675948"},{"key":"2025073013074418000_11.1.e001319.39","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290629"},{"key":"2025073013074418000_11.1.e001319.40","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/jhep.2003.50276","article-title":"Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"38","author":"Pomier-Layrargues","year":"2003","journal-title":"Hepatology"},{"key":"2025073013074418000_11.1.e001319.41","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0010.8661"},{"key":"2025073013074418000_11.1.e001319.42","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/lt.500060326","article-title":"Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial","volume":"6","author":"Mitzner","year":"2000","journal-title":"Liver Transplantation"},{"key":"2025073013074418000_11.1.e001319.43","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.cgh.2023.06.006","article-title":"Current pharmacologic therapies for hepatorenal syndrome-acute kidney injury clinical","volume":"21","author":"Duong","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025073013074418000_11.1.e001319.44","doi-asserted-by":"crossref","unstructured":"Roy P , Minhaz N , Shah-Riar P , et al . A comprehensive systematic review of the latest management strategies for hepatorenal syndrome: a complicated syndrome to tackle cureus. Cureus 2023;15. doi:10.7759\/cureus.43073","DOI":"10.7759\/cureus.43073"},{"key":"2025073013074418000_11.1.e001319.45","article-title":"Role of terlipressin in patients with hepatorenal syndrome-acute kidney injury admitted to the ICU: a substudy of the CONFIRM trial","volume":"5","author":"Karvellas","year":"2023","journal-title":"Crit Care Explor"},{"key":"2025073013074418000_11.1.e001319.46","doi-asserted-by":"crossref","unstructured":"Bass SN . Terlipressin compared with other vasoconstrictors(norepinephrine-midodrine and octreotide. Cleve Clin J Med 2023;90. doi:10.3949\/ccjm.90a.23037","DOI":"10.3949\/ccjm.90a.23037"},{"key":"2025073013074418000_11.1.e001319.47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40899.x"},{"key":"2025073013074418000_11.1.e001319.48","first-page":"56","article-title":"Captopril in low dose associated with octreotide in hepatorenal syndrome: a randomized study","volume":"38","author":"Chelarescu","year":"2003","journal-title":"J Hepatol"},{"key":"2025073013074418000_11.1.e001319.49","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.014"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2023-001319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T20:07:56Z","timestamp":1753906076000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2023-001319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,4,17]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/bmjgast-2023-001319"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2023-001319","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}